In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer. In this study, tumors were reduced in six out of 16 patients treated with the combination, including one case in which the cancer disappeared.
The study tested mirvetuximab soravtansine and pembrolizumab in patients with folate receptor-α (FRα) positive recurrent microsatellite stable (MSS) / mismatch repair proficient (pMMR) serous endometrial cancer. The study met its primary endpoint, and the results support continued study of the combination.
“This is a really encouraging response rate,” said principal investigator Rebecca Porter, MD, PhD, a medical oncologist in the Gynecological Oncology Program of Dana-Farber’s Susan F. Smith Center for Women’s Cancers. “This study underscores the potential benefits of combining antibody drug conjugates with immunotherapies for this patient group.”
Porter presents results of this study at the American Association for Cancer Research (AACR) Annual Meeting on Sunday, April 7, in San Diego, Calif.
